기업
Huons is launching a Phase 3 clinical trial of a combination drug for dry eye syndrome in Korea
바이오스펙테이터 Seunghyun Chon 기자
On 24th of last month, Huons announced that a Phase 3 clinical trial protocol for ‘HU007', which is a therapeutic product for dry eye syndrome, was approved by the Ministry of Food and Drug Safety.
This product is a new combination drug consisting of Cyclosporine and Trehalose, which are commonly used to treat dry eye syndrome. The company explains that it is an ophthalmic eye drop with compound therapeutic effects such as excellent protection of tear film and anti-inflammatory effect with an easier medication method. At the same time the dose of cyclosporine is reduced.
HU007 is under development with support from the Ministry of Commerce, Industry and Energy as part of the industrial core technology development project. Its safety and efficacy in patients with moderate-to-severe dry eye syndrome have been confirmed by a Phase 2 clinical trial which was completed in April this year.
Huons has completed registration of domestic patents for the preparation method of ophthalmic nanocomposite product containing Cyclosporine and Trehalose and relevant treatment. Overseas patent registration process is also underway.
"After successfully completing the Phase 3 clinical trial of this nanocomposite eye drop product, we will rise to the center of drug market for dry eye syndrome," said Mr. Key An Um, CEO of Huons.
